167 related articles for article (PubMed ID: 37229919)
1. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
[TBL] [Abstract][Full Text] [Related]
2. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
[TBL] [Abstract][Full Text] [Related]
3. Cervical Cytology Preserves Histologically Detected Surface Epithelial Slackening, Unique to the
Kitazono I; Akahane T; Yokoyama S; Kubota E; Nishida-Kirita Y; Noguchi H; Murakami M; Yanazume S; Kobayashi H; Tanimoto A
In Vivo; 2024; 38(1):321-333. PubMed ID: 38148087
[TBL] [Abstract][Full Text] [Related]
4. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
5. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
[TBL] [Abstract][Full Text] [Related]
6. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
7. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
[TBL] [Abstract][Full Text] [Related]
8. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract][Full Text] [Related]
10. Cytopathological features associated with POLE mutation in endometrial cancer.
Yanazume S; Iwakiri K; Kobayashi Y; Kitazono I; Akahane T; Mizuno M; Togami S; Tanimoto A; Kobayashi H
Cytopathology; 2023 May; 34(3):211-218. PubMed ID: 36727290
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.
Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z
J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
[TBL] [Abstract][Full Text] [Related]
14. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
15. Corded and hyalinized endometrioid endometrial carcinoma with high-grade features: a clinicopathological and TCGA-based molecular analysis.
Travaglino A; Arciuolo D; Santoro A; Raffone A; Pedone Anchora L; Piermattei A; Martinelli M; Mollo A; Onori ME; Minucci A; Inzani F; Fanfani F; Insabato L; Zannoni GF
Virchows Arch; 2023 Apr; 482(4):671-678. PubMed ID: 36550216
[TBL] [Abstract][Full Text] [Related]
16. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification.
Thompson EF; Huvila J; Jamieson A; Leung S; Lum A; Offman S; Lytwyn A; Sur ML; Hoang L; Irving J; van der Westhuizen N; Morin C; Bicamumpaka C; Azordegan N; Gougeon F; Ennour-Idrissi K; Senz J; McConechy MK; Aguirre-Hernandez R; Lui V; Kuo C; Bell C; Salisbury T; Lawson J; He E; Wang S; Chiu D; Kean S; Samouëlian V; Salvador S; Gotlieb W; Helpman L; Scott S; Wohlmuth C; Vicus D; Plante M; Talhouk A; Huntsman D; Parra-Herran C; Kinloch M; Grondin K; Gilks CB; McAlpine JN;
Mod Pathol; 2022 Dec; 35(12):1974-1982. PubMed ID: 36241860
[TBL] [Abstract][Full Text] [Related]
17. Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel.
Kobayashi Y; Kitazono I; Akahane T; Yanazume S; Kamio M; Togami S; Nohara S; Sakamoto I; Yokoyama S; Tabata K; Kobayashi H; Tanimoto A
Pathol Oncol Res; 2021; 27():1610013. PubMed ID: 35002543
[TBL] [Abstract][Full Text] [Related]
18. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
19. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
Heinze K; Cairns ES; Thornton S; Harris B; Milne K; Grube M; Meyer C; Karnezis AN; Fereday S; Garsed DW; Leung SCY; Chiu DS; Moubarak M; Harter P; Heitz F; McAlpine JN; DeFazio A; Bowtell DDL; Goode EL; Pike M; Ramus SJ; Pearce CL; Staebler A; Köbel M; Kommoss S; Talhouk A; Nelson BH; Anglesio MS
Clin Cancer Res; 2023 Sep; 29(17):3471-3483. PubMed ID: 37339172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
